Key facts
- Nantahala Capital Management, LLC filed SCHEDULE 13G for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 7.5%.
- Date of event: 31 Dec 2024.
Nantahala Capital Management, LLC - 31 Dec 2024 SCHEDULE 13G Report for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT)
- Filing Manager
- Nantahala Capital Management, LLC
- Reporting Manager
- Nantahala Capital Management, LLC
- Symbol
- IKT
- Shares outstanding
- 70,273,528 shares
- Disclosed Ownership
- 5,298,624 shares
- Ownership
- 7.5%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 16:32:39 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 13 Feb 2026
- SEC
- View on sec.gov
Key filing fact
Nantahala Capital Management, LLC disclosed 7.5% ownership in INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT) on 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:32.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 7.5% | 5,298,624 | 0 | 5,298,624 | /s/ Taki Vasilakis | Taki Vasilakis / Chief Compliance Officer | |
| Wilmot B. Harkey | 7.5% | 5,298,624 | 0 | 5,298,624 | /s/ Wilmot B. Harkey | Wilmot B. Harkey | |
| Daniel Mack | 7.5% | 5,298,624 | 0 | 5,298,624 | /s/ Daniel Mack | Daniel Mack |
CIK / CUSIP context first